A brief overview on one of the biggest challenges in the pharmaceutical industry: 5 key gram-negative drug-resistant bacteria strains are infecting millions, and killing thousands every year across the US and Europe. Xeraya Capital, together with Allecra Therapeutics are in the fight against these resistant bacteria.

1. XERAYA & ALLECRA
The Fight Against Gram-Negative
Drug-Resistant Bacteria

2. CURRENT CHALLENGES
BBC: November 2015 -
Analysis: Antibiotic
apocalypse
The World Health
Organization has warned
that "many common
infections will no longer have
a cure and, once again,
could kill unabated".
Source: http://www.bbc.com/news/health-21702647

3. CURRENT CHALLENGES
Nature: July 2013 -
Antibiotic resistance:
The last resort
Health officials are
watching in horror as
bacteria become
resistant to powerful
carbapenem antibiotics
—one of the last drugs on
the shelf.
Source: https://www.nature.com/news/antibiotic-resistance-the-last-resort-1.13426

4. CURRENT CHALLENGES
US CDC Report 2013
At least
2,049,442 illnesses
23,000 deaths
Source: https://www.cdc.gov/drugresistance/threat-report-2013/index.html

5. CURRENT CHALLENGES
Public Health England:
December 2015
Across Europe
25,000
people die each year
as a result of hospital infections
caused by 5 key resistant bacteria
Source: https://www.gov.uk/government/publications/health-matters-antimicrobial-resistance/health-matters-antimicrobial-resistance

6. KNOW THE 5 Key Resistant Bacteria
Escherichia coli
(E. coli)
Klebsiella pneumoniae
(K.Pneumoniae)
Enterococcus faecium
Pseudomonas aeruginosa
Methicillin-resistant
Staphylococcus aureus
(MRSA)

7. Gram-negative
bacteria resist
Gram stain (plus
many antibiotics)
due to outer
membrane
Gram staining is a
widely-used test,
applying crystal violet
dye to bacterial cultures
GRAM NEGATIVE Bacteria

8. WHERE IS IT FOUND?
These resistance mechanisms
are often found in hospital-
acquired Gram-negative
bacterial infections, and are of
particular concern to doctors,
healthcare providers, to
patients and their families and
to governments around the
world

9. INCREASED INFECTIONS
17%
19%
17%
28%
32%
43%
40%
58%
E. COLI K.PNEUMONIAE P. AERUGINOSA ACINETOBACTER
Suscep8ble Resistant

10. CAUSE OF RESISTANCE
Antibiotic consumption increased
by 6.5% over the past 4 years in
England. Prescribing is measured
as the defined daily dose (DDD) of
antibiotics taken by an individual
per 1,000 inhabitants per day.
Prescribing increased from 21.6
DDD per 1,000 inhabitants per day
in England in 2011 to 23 DDD per
1,000 inhabitants per day in 2014.

11. Percentage of invasive isolates
with combined resistance
Escherichia coli Pseudomonas aeruginosa

12. LOW DISCOVERY OF NEW ANTIBIOTICS
Public Health England:
December 2015
The discovery of new
classes of antibiotics is at
an all-time low.
It has been 30 years since a
new class of antibiotics was
last introduced.
Only 3 of the 41 antibiotics
in development have the
potential to act against the
majority of the most
resistant bacteria.
Source: https://www.gov.uk/government/publications/health-matters-antimicrobial-resistance/health-matters-antimicrobial-resistance

13. GLOBAL EFFECT
Antibiotics are a vital tool for
modern medicine. Not only for the
treatment of infections such as
pneumonia, meningitis and
tuberculosis.
We also need them to avoid
infections during chemotherapy,
caesarean sections and other
surgery.
Source: https://www.gov.uk/government/publications/health-matters-antimicrobial-resistance/health-matters-antimicrobial-resistance

14. TREATMENT STRATEGY
To develop extended spectrum β-
lactamase inhibitor known as AAI101
By inhibiting β-lactamases;
Allecra’s new medicine directly
tackles emerging resistance
mechanisms of certain hard-to-
treat bacteria.
AAI101 is delivered in combination
with the powerful 4th generation
cephalosporin antibiotic, cefepime.
AAI101
Cefepime

15. About ALLECRA THERAPEUTICS
Allecra Therapeutics, a clinical stage
biopharmaceutical company, was
established in 2013
Allecra Therapeutics is situated in
the BioValley Life Sciences region in
the Upper Rhein valley which
encompasses northwest
Switzerland, southwestern Germany
and the Alsace region of France
Dedicated to the development of
novel treatments to combat multi
drug-resistant bacterial infections

16. Timeline
2013
Allecra Founded
HQ in Germany
Scientific Operations in France
2016
Awarded SERIES B
December 2017
Xeraya joins as new Investor for
New Staged Financing Deal
First Tranche
February 2018
FDA Announces Fast Track for
AAI101
March 2018
Completes Phase II
Ready for Phase III
Well-tolerated
High microbial eradication & cure

17. Other Drugs to Combat Resistant Bacteria
By Novartis
Launched 2007
By Pfizer
Launched 2007